

Alan P Fields

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2169121/publications.pdf>

Version: 2024-02-01

44
papers

2,720
citations

236925

25
h-index

265206

42
g-index

44
all docs

44
docs citations

44
times ranked

3299
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. <i>Cancer Research</i> , 2022, 82, 90-104.	0.9	19
2	Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice. <i>Cancers</i> , 2022, 14, 796.	3.7	6
3	Editorial. <i>Advances in Biological Regulation</i> , 2021, 80, 100770.	2.3	0
4	Protein kinase C δ 1 and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. <i>Cell Reports</i> , 2021, 37, 110054.	6.4	6
5	Oncogenic protein kinase C δ 1 signaling mechanisms in lung cancer: Implications for improved therapeutic strategies. <i>Advances in Biological Regulation</i> , 2020, 75, 100656.	2.3	6
6	FoxM1 insufficiency hyperactivates Ect2 \rightarrow RhoA \rightarrow MDIA1 signaling to drive cancer. <i>Nature Cancer</i> , 2020, 1, 1010-1024.	13.2	6
7	Recurrent copy number gains drive PKC δ 1 expression and PKC δ 1-dependent oncogenic signaling in human cancers. <i>Advances in Biological Regulation</i> , 2020, 78, 100754.	2.3	5
8	Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma. <i>Cell Reports</i> , 2020, 30, 771-782.e6.	6.4	23
9	Protein kinase C δ 1 promotes UBF1 \rightarrow ECT2 binding on ribosomal DNA to drive rRNA synthesis and transformed growth of non-small-cell lung cancer cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 8214-8226.	3.4	7
10	Protein Kinase C δ 1 and Wnt/ β 2-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. <i>Cancer Cell</i> , 2019, 36, 156-167.e7.	16.8	45
11	Oncogenic Ect2 signaling regulates rRNA synthesis in NSCLC. <i>Small GTPases</i> , 2019, 10, 388-394.	1.6	19
12	Protein kinase C δ 1: A versatile oncogene in the lung. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1190886.	0.7	1
13	Functional Modulation of Gene Expression by Ultraconserved Long Non-coding RNA TUC338 during Growth of Human Hepatocellular Carcinoma. <i>iScience</i> , 2018, 2, 210-220.	4.1	12
14	Targeting oncogenic protein kinase C δ 1 for treatment of mutant KRAS LADC. <i>Small GTPases</i> , 2017, 8, 58-64.	1.6	5
15	Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. <i>Cancer Cell</i> , 2017, 31, 256-269.	16.8	97
16	A proof-of-concept trial of protein kinase C δ 1 inhibition with auranofin for the paclitaxel-induced acute pain syndrome. <i>Supportive Care in Cancer</i> , 2017, 25, 833-838.	2.2	7
17	Oncogenic PKC δ 1 decides tumor-initiating cell fate. <i>Cell Cycle</i> , 2016, 15, 2383-2384.	2.6	0
18	SOX2 Determines Lineage Restriction: Modeling Lung Squamous Cell Carcinoma in the Mouse. <i>Cancer Cell</i> , 2016, 30, 505-507.	16.8	9

#	ARTICLE	IF	CITATIONS
19	Protein Kinase C δ Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. <i>Cancer Cell</i> , 2016, 29, 367-378.	16.8	81
20	The chromosome 3q26 OncCassette: A multigenic driver of human cancer. <i>Advances in Biological Regulation</i> , 2016, 60, 47-63.	2.3	74
21	Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. <i>Oncotarget</i> , 2016, 7, 31097-31110.	1.8	50
22	A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. <i>Oncotarget</i> , 2015, 6, 15297-15310.	1.8	43
23	Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2015, 21, 505-513.	7.0	115
24	Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia. <i>Nature Communications</i> , 2015, 6, 6200.	12.8	79
25	The PRKCI and SOX2 Oncogenes Are Coamplified and Cooperate to Activate Hedgehog Signaling in Lung Squamous Cell Carcinoma. <i>Cancer Cell</i> , 2014, 25, 139-151.	16.8	265
26	Atypical Protein Kinase C δ as a human oncogene and therapeutic target. <i>Biochemical Pharmacology</i> , 2014, 88, 1-11.	4.4	88
27	PKC δ Maintains a Tumor-initiating Cell Phenotype That Is Required for Ovarian Tumorigenesis. <i>Molecular Cancer Research</i> , 2013, 11, 1624-1635.	3.4	60
28	Utility and Applications of Orthotopic Models of Human Non-Small Cell Lung Cancer (NSCLC) for the Evaluation of Novel and Emerging Cancer Therapeutics. <i>Current Protocols in Pharmacology</i> , 2013, 62, 14.27.1-14.27.17.	4.0	27
29	Protein kinase C δ expression and oncogenic signaling mechanisms in cancer. <i>Journal of Cellular Physiology</i> , 2011, 226, 879-887.	4.1	91
30	Protein kinase C iota in the intestinal epithelium protects against dextran sodium sulfate-induced colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1685-1697.	1.9	23
31	Oncogenic Activity of Ect2 Is Regulated through Protein Kinase C δ -mediated Phosphorylation. <i>Journal of Biological Chemistry</i> , 2011, 286, 8149-8157.	3.4	72
32	The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. <i>Advances in Enzyme Regulation</i> , 2010, 50, 190-200.	2.6	111
33	Protein Kinase C δ Is Required for Pancreatic Cancer Cell Transformed Growth and Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 2064-2074.	0.9	94
34	Atypical Protein Kinase C δ Is Required for Bronchioalveolar Stem Cell Expansion and Lung Tumorigenesis. <i>Cancer Research</i> , 2009, 69, 7603-7611.	0.9	94
35	Protein Kinase C δ and PKC δ : Collaborating Partners in Colon Cancer Promotion and Progression. <i>Cancer Research</i> , 2009, 69, 656-662.	0.9	42
36	Protein Kinase C δ Is an Effective Target for Chemoprevention of Colon Cancer. <i>Cancer Research</i> , 2009, 69, 1643-1650.	0.9	22

#	ARTICLE	IF	CITATIONS
37	Oncogenic <i>Ki-ras</i> promotes early carcinogenesis in the mouse proximal colon. <i>International Journal of Cancer</i> , 2008, 122, 2462-2470.	5.1	62
38	Protein kinase C isozymes as therapeutic targets for treatment of human cancers. <i>Advances in Enzyme Regulation</i> , 2008, 48, 166-178.	2.6	35
39	Protein kinase ζ : Human oncogene, prognostic marker and therapeutic target. <i>Pharmacological Research</i> , 2007, 55, 487-497.	7.1	113
40	A Novel Small-Molecule Inhibitor of Protein Kinase ζ Blocks Transformed Growth of Non-Small-Cell Lung Cancer Cells. <i>Cancer Research</i> , 2006, 66, 1767-1774.	0.9	154
41	Atypical Protein Kinase ζ Is an Oncogene in Human Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2005, 65, 8905-8911.	0.9	251
42	Atypical Protein Kinase ζ Plays a Critical Role in Human Lung Cancer Cell Growth and Tumorigenicity. <i>Journal of Biological Chemistry</i> , 2005, 280, 31109-31115.	3.4	168
43	Protein kinase ζ is required for Ras transformation and colon carcinogenesis in vivo. <i>Journal of Cell Biology</i> , 2004, 164, 797-802.	5.2	129
44	Protein Kinase ζ Activity Is Necessary for Bcr-Abl-mediated Resistance to Drug-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 1999, 274, 3927-3930.	3.4	104